30 citations
,
June 2017 in “Journal of cutaneous medicine and surgery” Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.
47 citations
,
July 2014 in “European Journal of Pharmaceutics and Biopharmaceutics” Scientists created a gel with nanoparticles to deliver medicine to hair follicles effectively.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
19 citations
,
July 2019 in “Journal of Endocrinology” GTx-024 and Danazol affect the uterus like DHT, while GTx-007 has little impact.
January 2021 in “Faculty of 1000 Research Ltd” Phytochemicals may offer safer alternatives to synthetic drugs for prostate cancer treatment.
January 2008 in “xPharm: The Comprehensive Pharmacology Reference” 1 citations
,
March 2022 in “Journal of The American Academy of Dermatology” Adjusting minoxidil dosage may be safer than using bicalutamide for hair loss in women.
14 citations
,
October 1977 in “The Lancet” April 2009 in “Journal of Pain” Finasteride reduces pain in male rats and works better with testosterone.
2 citations
,
November 2004 in “Blood” RXRa is crucial for Th2 immune cell development and may link nutrition to immune health.
Newer retinoid drugs are effective for skin conditions but have significant side effects.
60 citations
,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
May 2026 in “Frontiers in Pharmacology” Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.
34 citations
,
September 1997 in “Acta Dermato Venereologica” RXR agonists may promote hair growth in humans.
April 2023 in “Journal of Investigative Dermatology” The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.
4 citations
,
November 2021 in “Journal of The American Academy of Dermatology” Bicalutamide may reduce unwanted hair growth caused by minoxidil in women with hair loss.
6 citations
,
September 1998 in “The Journal of The British Menopause Society” Testosterone replacement may help postmenopausal women with sexual function and bone density, but suitable treatments are limited.
157 citations
,
December 2015 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
September 2024 in “Journal of Cutaneous and Aesthetic Surgery” Bicalutamide may help treat female pattern hair loss.
3 citations
,
August 2022 in “JAAD case reports” A woman developed swelling in her body after taking low-dose oral minoxidil for hair loss, but it resolved after stopping the medication.
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
October 2025 in “Actas Dermo-Sifiliográficas” RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.
11 citations
,
January 2000 in “The Journal of Steroid Biochemistry and Molecular Biology” LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.
2 citations
,
May 2020 in “JAAD case reports” Ruxolitinib can cause a delayed skin reaction on the nose.
1 citations
,
March 2026 in “American Journal of Clinical Dermatology”
37 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Ruxolitinib can help regrow hair in severe alopecia areata.
5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
40 citations
,
December 2016 in “Journal of Ovarian Research” Rutin may help treat symptoms of polycystic ovary syndrome (PCOS) in rats.